Patients with recurrent platinum-resistant ovarian cancer are needed for a study to research the combination of abemaciclib and olaparib

UVA Tracking #
Principal Investigator
Linda R Duska
Anne Gabel
Contact Email
Contact Phone
Official Trial Title
A phase 1/1b dose escalation study of abemaciclib and olaparib for recurrent platinum-resistant ovarian cancer
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who have recurrent platinum-resistant ovarian cancer. This study will look at the effects of the combination of two drugs: a kinase inhibitor (Decitabine) and a PARP inhibitor (Olaparib). The goal of the study is to find out if abemaciclib and olaparib can be taken safely together in ovarian cancer that has come back.

The total length of your participation in unknown. Each cycle is 28 days and the number of cycles you complete depends on how you respond to the study treatment. Once you are off treatment, you will need to come in for one more visit. Any procedures being done above and beyond standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: